Alexander Petersen

ANNOUNCEMENT: Peptides for Health Optimization A Complete Practitioner Guide to Peptide Fundamentals, Clinical Reasoning, and Advanced Stacking Peptides are no longer a niche topic. They’re now part of mainstream conversations across recovery, performance, metabolic health, neuroprotection, and longevity medicine—yet many practitioners are still forced to learn through fragmented information, informal protocols, and inconsistent sourcing. That’s why we created this course. Peptides for Health – Optimizing Human Potential & Recovery is a structured, clinically-relevant training designed to help practitioners: • Understand peptide fundamentals (mechanisms, signaling, tissue targets, kinetics, clinical intent) • Evaluate evidence and safety (risk screening, contraindications, red flags) • Integrate responsibly within scope, ethics, and legal boundaries • Build advanced stacking strategies using a clear framework: Goal → System → Mechanism → Sequencing → Monitoring • Develop personalized approaches for recovery, inflammation, metabolic dysfunction, sleep/stress dysregulation, cognitive decline risk, and healthy aging Core learning pillars include: 1. Metabolic Health & Body Composition 2. Neuroprotection, Brain Aging & Mood 3. Sleep, Stress & Neuroendocrine Regulation 4. Repair, Recovery, Inflammation & Tissue Healing 5. Cardiac, Fibrotic & Vascular Considerations 6. Advanced Longevity Concepts Included clinical tools: peptide decision trees, intake/screening checklists, client communication templates, stack-builder worksheets, and a professional practice framework. Important note: This course is educational and evidence-informed. It does not replace medical care and does not provide instructions for self-prescribing. Where peptides are regulated, we focus on professional scope, safe referral pathways, and responsible clinical reasoning. 👉 Reply “PEPTIDES” for enrolment details, or message us for the syllabus + start dates.

2

Does it make sense to chase #longevity if the extra time has no #purpose? Right now, billions in capital and talent are rushing into longevity and #healthspan. We talk about “QALYs, VSLs, GDP gains”, and some try to convince policy makers by talking about national “time stocks” worth trillions or even quadrillions. We know an extra healthy year of life can be worth several percent of GDP in economic models. But economics only tells us what longer life is „worth” if people already have a reason to get out of bed. ✅My2_cents Neuroscience and philosophy of time are quietly reminding us of something uncomfortable: we don’t actually experience “more years” as extra blocks on a timeline. Our brains construct a sense of flow, continuity and a persisting self out of discrete snapshots of experience. The “extra time” we buy with longevity science only becomes real if those snapshots are filled with meaning, relationships and contribution — not just more efficient consumption or more years in low-grade boredom. At the same time, gerontology is brutally clear: ➡️Older adults with a strong sense of purpose live longer and healthier. #Loneliness and social isolation erase healthspan, increasing mortality, dementia, depression and cardiometabolic disease risk. ⚠️In other words: purpose is already a longevity intervention. So what does this mean for the longevity industry? If your company is in the business of adding years, you should also be in the business of designing what those years are for. So here are a few hard questions for longevity workers, boards, investors and C‑suites: 👉 Are we only pulling the “make more time” lever (extending lifespan, healthspan), or are we also enriching “brain time” — how people can use attention, cognition and emotion in those added years? 👉 Does our science come with an ecosystem for connection, identity and contribution (work, caregiving, creativity, community) so extra decades don’t turn into a large, lonely waiting room? 👉When you back “longevity”, are you investing in more time — or in the human capacity to do something worthwhile with it? 20251125—10850

77

18 Comments

We backed Vivtex early grounded in Minnow’s conviction that delivery architecture — not just molecules — would define the next phase of metabolic therapeutics. Less than a year later, the $2.1B licensing deal with Novo Nordisk reinforces the idea that durable platforms compound when technical depth meets real demand. Proud to support teams building frontier technologies.

34

2 Comments

The question of origin and quality applies far beyond peptides — it's the same conversation we need in supplements and most of what practitioners recommend. When the supply chain is murky, outcomes become unpredictable. Appreciate you pushing for a higher bar here Peter Rivera

1

In early-stage biotech, the biggest leadership advantage often comes from looking where others aren’t. In her latest article, my colleague, Jo Neuman shares why “step-up” executives, or leaders taking on the C-suite for the first time, are worth betting on. They bring agility, curiosity, and real operating grit to the table. Learn more: https://lnkd.in/e5XqVfgP

13